{"disease":{"id":"urinary-bladder","name":"urinary bladder"},"drugs":{"marketed":[{"drug_id":"intravesical-solution","indication_name":"BCG-refractory CIS of the urinary bladder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Intravesical Solution","company_name":"Ankara Training and Research Hospital","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"bacillus-calmette-guerin","indication_name":"Treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bacillus-calmette-guerin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Mycobacterium tuberculosis","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"gluconolactone","indication_name":"Urinary bladder stone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Renacidin","generic_name":"GLUCONOLACTONE","company_name":"United Guardian","drug_phase":"marketed","molecular_target":"Glucosylceramidase","drug_class":"Calculi Dissolution Agent [EPC]","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"bcg","indication_name":"Treatment of carcinoma in situ (CIS) of the urinary bladder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01972841","title":"This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3527,"lead_sponsor_name":"Astellas Pharma Europe B.V.","has_results":true},{"nct_id":"NCT00688688","title":"Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2792,"lead_sponsor_name":"Astellas Pharma Inc","has_results":true},{"nct_id":"NCT00689104","title":"Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2336,"lead_sponsor_name":"Astellas Pharma Inc","has_results":true},{"nct_id":"NCT01908829","title":"A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2174,"lead_sponsor_name":"Astellas Pharma Europe Ltd.","has_results":true},{"nct_id":"NCT00662909","title":"A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2149,"lead_sponsor_name":"Astellas Pharma Inc","has_results":true},{"nct_id":"NCT00912964","title":"A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2030,"lead_sponsor_name":"Astellas Pharma Inc","has_results":true},{"nct_id":"NCT01638000","title":"A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1887,"lead_sponsor_name":"Astellas Pharma Europe Ltd.","has_results":true},{"nct_id":"NCT02045862","title":"A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1829,"lead_sponsor_name":"Astellas Pharma Europe B.V.","has_results":true},{"nct_id":"NCT06087016","title":"Urinary Markers by SpectrosCopy: Diagnostic Aid in oncologY - Application to Urological Cancers","phase":"","overall_status":"UNKNOWN","enrollment_count":1800,"lead_sponsor_name":"CHU de Reims","has_results":false},{"nct_id":"NCT02386072","title":"A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)","phase":"","overall_status":"COMPLETED","enrollment_count":1524,"lead_sponsor_name":"Astellas Scientific & Medical Affairs, Inc.","has_results":false},{"nct_id":"NCT01314872","title":"A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1395,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT01340027","title":"A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1307,"lead_sponsor_name":"Astellas Pharma Europe B.V.","has_results":true},{"nct_id":"NCT03536221","title":"What is the Prevalence of Female Pelvic Floor Disorders in Minnesota?","phase":"","overall_status":"COMPLETED","enrollment_count":1200,"lead_sponsor_name":"University of Minnesota","has_results":false},{"nct_id":"NCT00966004","title":"A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1139,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false},{"nct_id":"NCT01043666","title":"A Study of YM178 in Subjects With Symptoms of Overactive Bladder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1126,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false},{"nct_id":"NCT03807024","title":"Age-specific Prevalence and Comparisons of UDS and Bladder Diary Between OAB-wet and -Dry Women","phase":"","overall_status":"COMPLETED","enrollment_count":1071,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT04389632","title":"A Study of Sigvotatug Vedotin in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1006,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT05621837","title":"Quantifying Systemic Immunosuppression to Personalize Cancer Therapy","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT02320773","title":"A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice","phase":"","overall_status":"COMPLETED","enrollment_count":863,"lead_sponsor_name":"Astellas Pharma Europe Ltd.","has_results":false},{"nct_id":"NCT03661320","title":"A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":855,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT00527033","title":"A Study of YM178 in Patients With Symptomatic Overactive Bladder","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":842,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false},{"nct_id":"NCT05792033","title":"Multicentric Prospective T1 Urinary Bladder Cancer Registry","phase":"","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Medical University of Vienna","has_results":false},{"nct_id":"NCT03560778","title":"Comparisons of Urodynamic, Bladder Diary, Quality of Life Parameters Between OAB-wet and OAB-dry Female Patients","phase":"","overall_status":"COMPLETED","enrollment_count":623,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT05007106","title":"MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":613,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT07429994","title":"Predictors of Trifecta Achievement After HoLEP","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":604,"lead_sponsor_name":"Ondokuz Mayıs University","has_results":false},{"nct_id":"NCT03924895","title":"Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":595,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT04241185","title":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":520,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT04658862","title":"A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":518,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT01631552","title":"Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":515,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT04718948","title":"Multimodal Spectroscopy to Detect Urothelial Cancer in Urine","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"University of Florence","has_results":false},{"nct_id":"NCT05337189","title":"A Multicenter Clinical Trial of Urine DNA Testing for Bladder Cancer in China","phase":"","overall_status":"RECRUITING","enrollment_count":482,"lead_sponsor_name":"Creative Biosciences (Guangzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT04429360","title":"What is the Effect of Prolapse Surgery on Voiding?","phase":"","overall_status":"UNKNOWN","enrollment_count":453,"lead_sponsor_name":"Universiteit Antwerpen","has_results":false},{"nct_id":"NCT03043287","title":"Voiding Efficiency, a Predictor of Clean Intermittent Catheterization (CIC)","phase":"","overall_status":"COMPLETED","enrollment_count":420,"lead_sponsor_name":"Allergan","has_results":false},{"nct_id":"NCT05810623","title":"Single-Dose Intravesical Chemotherapy After Diagnostic URS","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":394,"lead_sponsor_name":"David D'Andrea","has_results":false},{"nct_id":"NCT03320850","title":"BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":383,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT04534075","title":"Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":354,"lead_sponsor_name":"Sahlgrenska University Hospital","has_results":false},{"nct_id":"NCT03288545","title":"A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":348,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT06892860","title":"Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":320,"lead_sponsor_name":"Queen Mary University of London","has_results":false},{"nct_id":"NCT03866382","title":"Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":314,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06833073","title":"A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":308,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT06479720","title":"Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Mackay Memorial Hospital","has_results":false},{"nct_id":"NCT05968885","title":"Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Mackay Memorial Hospital","has_results":false},{"nct_id":"NCT01613586","title":"A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":287,"lead_sponsor_name":"Astellas Pharma Europe B.V.","has_results":false},{"nct_id":"NCT01884753","title":"Correlations of 3D Urethral and Paraurethral Sonographic Findings With Urodynamic Studies, Lower Urinary Tract Symptoms & Sexual Dysfunction in Female Patients With Lower Urinary Tract Symptoms.","phase":"","overall_status":"COMPLETED","enrollment_count":279,"lead_sponsor_name":"Far Eastern Memorial Hospital","has_results":false},{"nct_id":"NCT05362292","title":"TReating Incontinence for Underlying Mental and Physical Health","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":270,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT01604928","title":"Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":260,"lead_sponsor_name":"Astellas Pharma Europe B.V.","has_results":false},{"nct_id":"NCT02660359","title":"Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":258,"lead_sponsor_name":"Ipsen","has_results":true},{"nct_id":"NCT02820844","title":"Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":250,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03061760","title":"Effects of Urinary Bladder Hypertrophy on Urge Urine Incontinence After Radical Prostatectomy","phase":"","overall_status":"UNKNOWN","enrollment_count":250,"lead_sponsor_name":"Collegium Medicum w Bydgoszczy","has_results":false},{"nct_id":"NCT02590250","title":"A Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in India","phase":"","overall_status":"COMPLETED","enrollment_count":250,"lead_sponsor_name":"Allergan","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}